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Background: Around 3.3 million children worldwide are infected with HIV and 90% of them live in sub-Saharan
Africa. Our study aimed to estimate adherence levels and find the determinants, facilitators and barriers of ART
adherence among children and teenagers in rural Tanzania.
Methods: We applied a sequential explanatory mixed method design targeting children and teenagers aged 2–19
years residing in Ifakara. We conducted a quantitative cross sectional study followed by a qualitative study combining
focus group discussions (FGDs) and in-depth interviews (IDIs). We used pill count to measure adherence and defined
optimal adherence as > =80% of pills being taken. We analysed determinants of poor adherence using logistic
regression. We held eight FGDs with adolescent boys and girls on ART and with caretakers. We further explored
issues emerging in the FGDs in four in-depth interviews with patients and health workers. Qualitative data was
analysed using thematic content analysis.
Results: Out of 116 participants available for quantitative analysis, 70% had optimal adherence levels and the
average adherence level was 84%. Living with a non-parent caretaker predicted poor adherence status. From the
qualitative component, unfavorable school environment, timing of the morning ART dose, treatment longevity,
being unaware of HIV status, non-parental (biological) care, preference for traditional medicine (herbs) and
forgetfulness were seen to be barriers for optimal adherence.
Conclusion: The study has highlighted specific challenges in ART adherence faced by children and teenagers.
Having a biological parent as a caretaker remains a key determinant of adherence among children and teenagers.
To achieve optimal adherence, strategies targeting the caretakers, the school environment, and the health system
need to be designed.
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In-depth interviewsBackground
At the end of 2012, an estimated 35.3 million [32.2–38.8
million] people were living with HIV. The UNAIDS
global report 3.3 million children had HIV globally, 2.9
million in sub-Saharan Africa [1]. In 2012, there were
230,000 children living with HIV and 1.3 million or-
phaned by AIDS in Tanzania [2]. Treatment of HIV* Correspondence: dnyogea@ihi.or.tz
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unless otherwise stated.infected patients with ART has resulted in a dramatic re-
duction in HIV related morbidity and mortality [3]. Suc-
cessful treatment results in virological suppression, an
increase in the CD4+ T cells count, and improvement in
the clinical well-being of the individual, manifesting as
weight gain and resolution or control of opportunistic
infections [4]. Adherence to treatment regimens is a pre-
requisite for the efficacy and durability of any ART [5,6].
According to recent studies, ART regimens require 70–
90% adherence in order to be effective [7]. Some studies
show that viral suppression for patients treated withl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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is possible with adherence levels ranging from 54%–
100% [8]. Poor adherence to ART regimens results in in-
complete suppression of HIV replication and emergence
of resistance to ART that increase the potential for treat-
ment failure, compromising future treatment options
and leading to increased risk of mortality [9]. The World
Health Organization (WHO) recommends regimens in-
volving tablets and that syrup or liquid formulation be
prescribed for children depending on weight, however
recognizing that lack of refrigeration and the supply
chain for syrup or liquid forms may bring some chal-
lenges [10]. Children and adolescents with HIV often
face other life stressors that affect their ability to achieve
optimum adherence, including parental HIV disease,
poverty, and limited or inconsistent social support [11].
Availability of adherence information assists health care
workers in providing optimal care to patients.
In Tanzania, studies on adherence have been primarily
focused on adults and less information is available on
children and teenagers. As children form a special group
due to lengthy expected time on ART and challenges
faced during adolescence, more information is needed in
order to design appropriate interventions to improve or
maintain sufficient ART adherence levels. This study
estimated adherence levels, investigated determinants
for ART adherence and explored barriers and facilitators
of adherence among children and teenagers in rural
Tanzania.
Methods
Study design
We used a sequential explanatory mixed methods study
design. A quantitative cross sectional study was followed
by a qualitative study combining focus group discussions
(FGDs) and in-depth interviews (IDIs).
Study setting
We conducted the study in Ifakara town in the Kilombero
district of the Morogoro region for 6 months between
November 2011 and April 2012. The study was per-
formed within the observational HIV cohort, Kilombero
and Ulanga Antiretroviral Cohort (KIULARCO), at the
Chronic Diseases Clinic Ifakara (CDCI) in St Francis
Referral Hospital (SFRH). The CDCI started providing
HIV care and treatment in 2005 in Ifakara [12-14] in
accordance with guidelines of the Tanzanian National
AIDS Control Program (NACP) [15]. Follow up visit
are scheduled every 3–6 months. All patients were
treated as per Tanzania National Guideline for HIV/
AIDS treatment [16]. During the study, liquid formula-
tions were only available for prophylaxis among HIV-
exposed infants and not as treatment for HIV infected
children. Early infant diagnosis (EID) was unavailable atCDCI during the study period but has been recently
introduced.
Quantitative component
Study participants
We targeted all patients attending the CDCI who were
on ART and aged between 2–19 years. Patients were in-
cluded if they had visited the CDCI for a drug refill be-
tween 10–150 days prior to the start of the study. The
study participants were traced and interviewed at home
during an unannounced visit. For the quantitative data
collection, children below 18 years were interviewed to-
gether with their parents/caretakers. We did not inter-
view children who were critically ill.
Data collection
The interviews were conducted in Swahili, the national
language of Tanzania and commonly spoken by Ifakara
residents. For the quantitative study, data were collected
by trained non-medical field interviewers using a struc-
tured questionnaire.
Variables
Outcome
The primary outcome variable was ART adherence. Per-
centage adherence was measured as the ratio of drugs
actually taken to the drugs supposed to be taken (pre-
scribed) by using the formula [Adherence = (Number of
pills dispensed - Number of pills remained) × 100)/
(Number of pills prescribed per day × number of days
between pharmacy visit and home visit)]. The drugs ac-
tually taken were estimated by calculating the number of
dispensed drugs minus the drugs found during the un-
announced visit. This was assessed using pill count,
which was first calculated by field worker and then veri-
fied by a field manager. The overall average adherence
was calculated in two steps. Since commonly used ART
regimens involve a combination of three drugs and are
dispensed as either a fixed dose or a separate combin-
ation, the adherence percentage level for each drug was
calculated. Then the average adherence for each regimen
was assessed for each individual. Participants were en-
couraged to provide all ART pills that were dispensed at
the clinic in the last visit plus the ones that remained
from the prior visit. For individuals whose adherence
levels exceeded 100%, the adherence level was capped at
100%. For the analysis, optimal adherence was defined
as > =80%.
Predictors of ART adherence
The determinants for ART adherence were : gender, pill
burden, visit to a local healer (who claimed to have a
cure for HIV/AIDS), disease progression measured by
age-specific immunological criteria (immune-suppressed
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CD4 < 350 cells/mm3 for children ≥ 6 years) and WHO
clinical staging (I/II versus III/IV), child awareness of
HIV disease, parental status (both parents, single parent,
or non-parental caretaker (non-parental caretaker in-
cluded patients grandmother, sister, aunt, uncle or step
mother)), distance to the clinic, duration under ART,
knowledge about ART treatment duration, HIV support
group membership, adherence assistance (parents versus
others), socioeconomic status (SES) and education level.
Education level was assessed by combining age and
school attendance (preschool age (2–5 years), children
of school age (6 years or more) who never went to
school, children of school age and in school, children of
secondary school age (12 years or more) but in primary
school, and children of secondary school age and in sec-
ondary school).
Collection of socioeconomic status (SES) data
Data on socioeconomic status was collected using an
asset survey from June 2011 to September 2011 among
1935 patients under ART enrolled in KIULARCO. ‘Low’,
‘middle’ and ‘high’ tertiles of socio-economic status were
constructed using principal component analysis [17] on
scores calculated from asset ownership (electricity, lamp,
radio, television, mobile phone, land line, iron, refriger-
ator, wrist watch, bicycle, motor bike, motorcar, and hav-
ing a bank account) and the house’ building materials
(mud, bamboo, wood, tiles, cement, carpet, grass, post,
brick (sun), brick (fire), wood, cement bricks, iron
sheets, tiles, concrete and fabricated bricks).
Bias
Classification bias of adherence level was minimized by
training field interviewers on how to assess and calculate
adherence percentages as well as cross-checking adher-
ence estimates for confirmation by a field manager
before data entry. To reduce social desirability bias, in-
formation on level and determinants of adherence was
collected by non-medical staff.
Sample size
We included all active patients aged 2–19 years under
ART attending the CDCI within the last 150 days,
i.e. 163 patients. Using an alpha of 5%, a power of 90%
and a hypothesized adherence prevalence of 70% in the
reference category, with this effective sample size we
were able to statistically significantly detect a risk ratio
of 1.4.
Data processing and analysis
Quantitative data were double entered using EPI-DATA
(EpiData Association, Odense, Denmark) and analyzed
using STATA 11.0 (STATA Corp., College Station, Texas,USA). Chi square test was used to assess the association
between the variables studied and the response status and
with the adherence categories. Logistic regression was
used to estimate associations between adherence and risk
factors. Participants with missing adherence (outcome)
data were excluded from analysis. Sensitivity analyses were
done to assess the potential influence of missing values for
predictor variables. Variables with a P-value of less than
0.25 were eligible for inclusion in the multivariable ana-
lysis. Since this applied to only one variable (parental sta-
tus), we reported only the univariate analysis. We assessed
if non-response was associated with variables under the
study. Variable(s) that were found to predict adherence
were investigated in the qualitative part to understand the
mechanism underling such association.
Qualitative component
Population and sample
We targeted adolescents aged 13–17 years who were on
ART who were aware of their HIV status and the parent
or non-parent caretakers in charge of the child. The
Tanzanian definition of adolescents has been adopted
from the WHO [18] which defines adolescent as a young
person aged between 10–19 years. However, for the pur-
pose of this study, we interviewed adolescents of age 13
to 17 years assuming that these adolescents will be
capable of expressing their views on issues related to
treatment experience and challenges. From the CDCI
database we randomly sampled boys and girls aged 13–
15 and 16–17 and within each group conducted one
FGD. In total we included 35 HIV infected adolescents
in the FGDs. We also conducted FGDs with 21 parents
or caretakers living with HIV infected adolescents (on
ART) residing within the study site, two FGDs with
women and two with men. Each FGD comprised of 7–8
participants. We opted for the FGDs due to their useful-
ness in enhancing social interaction different from other
qualitative methods [19], high face validity [20] and their
relevance in providing opportunity to interview several
participants systematically and simultaneously [21]. To
deepen our understanding of issues emanating from
FGDs, we subsequently conducted four IDIs, with a
16 year old male patient, a 43 year old male caretaker of
an eight year old child and with two healthcare providers
(a medical doctor and a nurse).
Data collection
An interview topic guide with specific themes aided the
FGDs. The was guide composed of broader themes that
relate to attitude and perception on ART, perceived bene-
fit of ART treatment, perceived risk of treatment, know-
ledge about treatment adherence, family strategies to
ensure treatment adherence, children’s experience with
treatment and perceived barriers to treatment adherence.
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[22], health behavior theories [23,24] and life experience/
observation. The second author who is a female social sci-
entist facilitated the discussions aided by a trained male
research assistant. To enhance freedom of expression dur-
ing FGDs, participants’ were facilitated by researchers of
matching sex and in a neutral venue, i.e. at a school after
school hours. The discussions were audio recorded follow-
ing permission from the participants. Throughout the
interview, free flowing discussion was encouraged and
some new topics which were raised in the first interview
were again probed in the next interviews following the
principles of grounded theory [23]. Unlike adults, chil-
dren’s explanations about barriers to treatment adherence
were in short segments, sometimes not very direct but
useful. The researcher took time to probe and motivate
children to provide their inside views and experience that
relates to taking the lifelong treatment.Data analysis
After the interviews, the research assistants transcribed
verbatim digitally audio recorded interviews in Swahili
language. The second author frequently reviewed the
transcripts using the side notes and relevant ideas were
noted. Thematic content analysis was used to process all
participants’ descriptions along with identification of
relevant concepts and ideas found in the transcripts
linked to the topics of inquiry [25].
Relevant ideas were categorized under specific themes
and later coded [26]. We included the pre-existing themes,
for example “attitude towards ART treatment” and “non-
parental care”. We also included emerged themes such asRefused
Missing adherence
information
(Excluded from the
analysis) n=7 (6%)
Patients approach
Included in the study
analysis n=116 (94%)
Interviewed patients, n=123 (75%)
Transfer**
n=12 (43%
Figure 1 Flow diagram of study participants of quantitative compone
Subjects had traveled outside Ifakara for various reasons. **These are patien“supportive school environment” and “unfriendly nature of
counseling services”.Ethical statement
The study received ethical clearance from National
Institute of Medical Research of Tanzania. Parents and
caretakers signed the informed consent to participate in
the study, both for themselves and on their children’s be-
half. Participating children assented to answer questions.
Records were anonymized and patients were identified
by unique identifiers during analysis and reporting. As
per routine procedures in the clinic, patients who had
poor adherence levels were further followed up by physi-
cians in the CDCI.Results
Data flow
There were 265 HIV patients <20 years of age attending
the clinic of whom 163 (62%) were currently on ART
(Figure 1). Forty patients (25%) were not interviewed be-
cause of refusal, non-availability or death. The reasons
for non-availability were undocumented transfer, an in-
correct home address or travel of the patient. For the
quantitative study, we interviewed 123 (75%) of 163 pa-
tients approached. Among the patients successfully
interviewed, seven were excluded from the analysis be-
cause they did not have adherence data (they did not
provide their pills during the home visit). We finally in-
cluded 116 children and adolescents in the analysis
(Figure 1). Non-response was not associated with the
variables under study (Table 1).Not available
ed 163
Died,
n=10 (25%)
Not interviewed, n=40 (25%)
)
On Travel*
n=2(3%)
Wrong address
n=15 (54%)
nt. *On Travel meant the patients was not within Ifakara town.
ts who transferred out without having transfer permit from the clinic.
Table 1 Summary of characteristics of patients by
response status
Responders Non-responders P-Value
Variable n % n %
Sex
Male 67 58 24 51
Female 49 42 23 49 0.40
Age categories (yrs)
2-5 30 26 16 34
6-11 46 40 15 32
12+ 40 34 16 34 0.51
WHO stage
Stage I & II 31 27 14 30
Stage III & IV 40 34 27 57
Missing 45 39 6 13 0.59
Distance to clinic
<5 km 93 80 43 91
>5 km 23 20 4 9 0.08
Duration on ART (yrs)
0-2 46 40 11 23
>3 60 52 20 43
Missing 10 9 16 34 0.43
WHO stage =World Health Organization clinical stage; yrs = years; km= Kilometers;
% = Column percentages.
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Sixty-seven (58%) of the participants were males. The me-
dian age was 9.8 years (interquartile range (IQR): 5.7 –
13.3, range 2–19), and 77 (66%) of the participants were
not living with both parents (out of these, 61% (47/77)
were not living with either parent). Patients had been tak-
ing ART for a median of 35.8 months (IQR: 23–46)
(Table 2). All participants were taking first line treatment
regimens based on 2 NRTIs + 1 NNRTI.
Adherence levels
The overall average ART adherence level was 84.2% with
a range from 2.3% to 100% and the proportion of
patients with adherence level of 80% or more was 70%
(81/116).
Determinants for adherence
From the logistic regression analysis, children living with
non-parent caretakers were more likely to have poor ad-
herence compared to children living with their parents
((OR = 2.84, 95% CI: (1.04-7.77)) (Table 3). Children liv-
ing with single parent or non-parent caretaker had lower
levels of optimal adherence compared to children living
with biological parents. The magnitude of association
between adherence and educational status was high,
but the evidence of association was statistically non-significant (children of primary school age (6 years or
more) who never went to school compared to preschool
age children, OR = 2.39, 95% CI: (0.69-8.28)). Children
who reportedly joined an HIV support group had a
lower proportion of optimal adherers compared to chil-
dren who were never members (OR =2.0, 95% CI 0.75-
5.27). The quantitative analysis showed no associations
between adherence levels and sex, education, duration
on ART, CD4+ T cells count, WHO clinical staging,
SES, ever visited traditional healer, pill burden and dis-
closure status.
Barriers and facilitators of adherence
The results of the FGDs and IDs complemented the
cross-sectional survey and shed further light on its find-
ings. The thematic analysis suggested a range of themes
influencing adherence to ART, many of which were
commonly shared among the FGD and IDIs participants.
The summary of the barriers and facilitators of ART ad-
herence are found in Table 4.
Facilitators of treatment adherence
Positive attitudes and perceived benefits towards treatment
Both children and caretakers reflected a positive attitude
towards treatment. This was indicated by the adoles-
cent’s expression of “feeling good with the treatment”
which was a common statement by most of the children.
Caretakers shared the same experience “we become
happy when we see health improvement of our children”.
Positive attitude towards treatment was also reflected
by the experiences reported by the groups in relation to
the perceived benefits of treatment. The most recurrent
themes related to the perceived benefits of treatment in-
cluded the ‘reduction of recurrent diseases’, “looking
healthy after the initiating ARV” , “living longer” , “getting
cured” , “ability to participate in economic activities” and
“ability to attend classes”.
The following excerpts indicate some of the related
themes:
“My son used to be sick every day, and he was very thin,
but after treatment initiation I can see that he is now
well, but I can see other children also, before they start
treatment they become very sick but after treatment
they change (their health status). [FGD, Female].
“Ooh, the treatment is good, like me I wasn’t like this,
before taking this treatment I had rashes all over my
body and I was so thin until my fellow children were
avoiding me and said she has AIDS, but when I
started taking the medicine, my condition changed
and I am now big and healthy”. [FGD, Girl].
Table 2 Summary of characteristics of participants by adherence categories
Optimal Suboptimal P-Value
Variables n % n %
Sex
Male 46 69 21 31
Female 35 71 14 29 0.75
Age-school
Pre-school age 2-5 yrs 23 77 7 23
>6 yrs never been to school 11 58 8 42
Primary school age and in primary 21 70 9 30
Secondary school but in primary 19 70 8 30
Secondary school age and in secondary 7 70 3 30 0.74
Baseline CD4 + cell count
Below 350 cells/mm3 33 66 17 34
Above 350cells/mm3 42 71 17 29
Missing 6 86 1 14 0.54
Age specific immunosuppression
Not Immunosuppressed 61 70 26 30
Immunosuppressed 16 67 8 33
Missing 4 80 1 20 0.83
Duration under ART
0-2 yrs 30 65 16 35
>2 yrs 41 68 19 32
Missing 10 100 0 0 0.09
Parental status
Both parent 32 82 7 18
Single parent 20 67 10 33
Non-parental caretaker 29 62 18 38 0.11
Knows that treatment is lifelong
Yes 57 70 24 30
No 24 69 11 31 0.85
Disclosure of HIV status
Yes 25 64 14 36
No 53 75 18 25
Missing 3 50 3 50 0.29
Adherence assistance
Parents 48 74 17 26
Non-parental adherence assistants 33 65 18 35 0.29
Visited traditional healer for HIV cure*
Yes 15 75 5 25
No 66 69 29 31
Missing 0 0 1 100 0.28
Pill burden
1 pill 35 69 16 31
2-3 pills 46 71 19 29 0.80
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Table 2 Summary of characteristics of participants by adherence categories (Continued)
Joined any HIV support group
Yes 12 57 9 43
No 69 73 26 27 0.16
WHO clinical staging
Stage I & II 20 65 11 35
Stage III & IV 26 65 14 35
Missing 35 78 10 22 0.33
Socioeconomic status
Low 30 73 11 27
Median 16 73 6 27
High 27 63 16 37
Missing 8 80 2 20 0.61
Poor adherence = less than 80%;optimal adherence = 80% or more; WHO =World Health Organization;yrs = years; * visited a healer who claimed to have a cure
for HIV/AIDS; Immune-suppressed if CD4 < 500 cells/mm3 for children aged <6 years and if CD4 < 350 cells/mm3 for children aged 6 years and above;% = Row
percentages; p = Chi2 P-value.
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Generally, participants were able to explain the meaning
of treatment adherence conditions. The most frequently
mentioned treatment adherence conditions included
“taking drugs in the morning and evening” , “taking drugs
without stopping” , “taking drugs before food” , “eating
fruits” and “abiding to the time of taking drugs without
changing”.
For those who were able to mention the risks of non-
adherence to treatment, they mostly mentioned recur-
rence of illness, suffering and death as reflected in the
following excerpts:
“Following treatment instructions it means taking
drugs every day because at times the body is used to
that. When you stop abruptly the body will get
problems because it will notice the difference. And the
body will get fevers which were over”. [FGD, Female].Treatment adherence barriers
Despite respondents clearly valuing ART, several barriers
existed for maintaining ART adherence in the social en-
vironment, in the health service delivery, and related to
the treatment and disease itself.Fear of stigma and consequences
Most caretakers and children were strongly opposed to
sharing the child’s treatment status with other people,
friends or relatives in the community due to fear of
mocking by other people in the community. Most chil-
dren and adolescents viewed taking their treatment pills
in front of their fellow children as unacceptable due to
negative reaction from other children in the community:“I can’t dare to tell any of my friends or neighbors that
my child is on treatment, because they will start
spreading this information to others”. [FGD, Male].
“When I take these drugs they (other children) will say,
“We do not know what he is suffering from. He is
taking drugs every day; but he is not getting cured”.
[FGD, Boy].
Enacted stigma also contributed to a lack of a support-
ive school environment. The school mates and teachers
mocked, segregated and stigmatized children with HIV
taking ART. Some children reported that they initially
used to take their drugs at school but have decided to
change and begin to take drugs at home due to some in-
sults from their fellow students.
“Parents fear disclosing their children’s HIV and
treatment status to teachers because of fear that their
children may be segregated. My child was pinned a
red label on his shirt by his teacher after he knew the
HIV and treatment status of the child”. [FGD, Male].
“In the past fellow schoolmates started mocking at me
that I have AIDS after they saw me taking ARV at
school. Later I had to change and started taking the
pills at home”. [FGD, Girl].
Non-parent caretaker
According to the FGD discussants, children who live
with their biological parents receive much more treat-
ment support and care as compared with children who
live with their caretakers.
Table 3 Univariate logistic models of poor ART adherence among children and teenagers in Ifakara, Tanzania (n = 116)
Univariate analysis
Variable OR 95% CI P-Value
Sex
Female 0.88 0.39-1.96 0.748
Age-School
Pre-school age 2-5 yrs 1
>6 yrs never been to school 2.39 0.69-8.28 0.170
Primary school age and in primary 1.41 0.45-4.45 0.560
Secondary school age but in primary 1.38 0.42-4.5 0.591
Secondary school age and in secondary 1.41 0.29-6.9 0.674
Baseline CD4 + cell count
Below 350 cells/mm3 1
Above 350 cells/mm3 0.79 0.35-1.77 0.561
Age specific immunosuppression
Not Immunosuppressed 1
Immunosuppressed 1.17 0.46-3.08 0.746
Duration under ART
0-2 years 1
>2 years 0.88 0.38-1.96 0.735
WHO stage
Stage I & II 1
Stage III & IV 0.98 0.37-2.61 0.966
Visited Traditional Healer for HIV cure*
No 1
Yes 0.76 0.25-2.28 0.623
Pill burden
1 pill 1
2-3 pills 0.90 0.41-2.0 0.803
Disclosure of HIV status
Yes 1
No 0.61 0.26-1.41 0.246
Joined any HIV support group
No 1
Yes 2.0 0.75-5.27 0.166
Adherence assistance
Parents 1
Non-parental adherence assistants 1.54 0.69-3.41 0.288
Knows that treatment is lifelong
No 1
Yes 1.65 0.71-3.84 0.246
Socio-economic status
Low 1
Median 1.02 0.32-3.3 0.970
High 1.62 0.64-4.08 0.310
Nyogea et al. BMC Infectious Diseases  (2015) 15:28 Page 8 of 13
Table 3 Univariate logistic models of poor ART adherence among children and teenagers in Ifakara, Tanzania (n = 116)
(Continued)
Parental status
Both Parents 1
Single parent 2.29 0.75-6.98 0.200
Non-parental caretaker 2.84 1.04-7.77 0.042
*Visited a healer who claimed to have a cure for HIV/AIDS; Poor adherence = less than 80%;optimal adherence = 80% or more; Immune-suppressed if CD4 < 500
for children aged <6 years and if CD4 < 350 for children aged 6 years and above; WHO =World Health Organization; yrs = years; CI = confidence interval;
OR = odds ratio.
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times it happens that you are sick and the father asks
the mother to take you to the hospital. When dad goes
to work, the step mother doesn’t take me for treatment
and I continue suffering”. [FGD, Boy].
Health service delivery factors
Some children and caretakers expressed their concern
about the counseling sessions offered at the health facil-
ity which combined adults and children all together.
Children felt that they need to have separate counseling
sessions so they can express their treatment challenges
freely without having adults interfering and can receive
the attention they need from the counselors.
“They combine us (children) with those (adults), when
we are there with them (adults) we cannot understand
things (information) and some of us cannot ask
questions or explain problems…. There should be someTable 4 Barriers to treatment adherence from the
qualitative component of the study–as derived from
focus group discussions and in-depth interviews
Category Treatment adherence barriers
Stigma related factors ▪ Fear of disclosure of child’s status to the
teachers and family members by parents
▪ Segregation by teachers and other
children
Lack of supportive
environment at home
▪ Inadequate support from parents
➢ Parents move to farming areas without
one to follow up on child’s treatment
schedule
➢ Men do not provide enough treatment
adherence support
➢ Extended family members do not
provide support
Lack of supportive
environment from school
▪ Teachers do not provide adequate
support to children on ART
Health service delivery
factors
▪ Lack of child friendly counseling services
▪ Inconvenient treatment schedule
▪ Longevity of treatment
Patient factor ▪ Forgetfulness
▪ Feeling betterseparate sessions for children and so the doctors could
listen nicely to children”. [FGD, Boy].
Not informed about HIV status
Some children expressed their concern that they were
not informed about their HIV status by their parents.
One child described his concern as follows:
“I grew up taking medicine without knowing the
disease that I was suffering. They kept on telling me
that I have malaria and until now they have not told
me anything with regards to HIV, but the doctor told
me that I am HIV positive and I feel bad that my
sister did not tell me”. [FGD, Boy].
Some parents also explained difficulties faced in dis-
closing HIV status to their children but once informed
the children were able to adhere with their treatment
schedule, as explained by one parent in the following
excerpt:
“I asked my child to take medicine without telling him
what he was suffering from. When I told him what he
was suffering from (HIV), it helped him to follow the
instructions. I told him that his mother died because of
the same problem and that he should not stop taking
drugs”. [FGD, Male].
Preference of traditional medicine
Some parents encourage their children to go beyond the
formal health sector and take traditional medicine in-
stead of drugs obtained at the health facility.
“Some parents do not want their children to take
medicines from the hospital. They give them
traditional medicines when it is obvious that the child
has AIDS”. [FGD, Boy].
Inconvenient treatment schedule and longevity of the
treatment (treatment fatigue)
Taking drugs in the morning before going to school was
not very patient-friendly as children often forget while
hurrying for school or felt sick if they were forced to
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cern as follows:
“My mother tells me to take drugs in the morning and
I sometimes wake up very early and no food prepared,
and when I take medicine (in the morning) I feel
nausea but I go to school just like that… and I try not
to miss school…”. [FGD, Boy].
Children and caretakers gave the impression that some
children are getting tired of taking the medications as
explained below:
“Some grown-up children may sometimes cheat that
they have taken drugs while they have not, because
they are tired and the parents believe that they have
already taken the drugs”. [FGD, Female].
“Some children are tired of taking medicine, I
remember one day when I was giving my child
medicine, and he told me that, ‘uncle if you want to
give me medicine give me even those for tomorrow’”.
[FGD, Male].
Forgetfulness and feeling better
Patients FGD discussants from both groups mentioned
the problem of forgetting to take drugs at the appropri-
ate time due to the intensity of their engagement in
games. At times, especially when patients observe some
health improvement, they do not have the motivation to
continue with treatment.
“There are others (children) who put priority on games
and when they are playing they forget to take drugs
completely”. [FGD, Boy].
“You find another person goes to the hospital and
when they are given drugs they take them for one
month and in the next month they stop taking these
drugs when they see that they are OK”. [FGD, Girl].
Discussion
This explanatory mixed-methods study among children
and teenagers attending a large HIV care and treatment
clinic showed that participants had a positive attitude to-
wards ART and 70% of the participants achieved desired
level of adherence (defined as 80% or higher). The pro-
portion of patients with acceptable levels of adherence
varies across several studies using different techniques of
evaluating adherence.
A review of ART adherence in low and middle-income
countries found a range in adherence level estimates
from 49% to 100% with 76% of articles reporting >75%adherence [27]. A study done in India showed 95.3%
[28] of the children had acceptable level of adherence
whilst a study done in Dar es Salaam showed 97% [29]
of children had optimal adherence. Another study done
in Ethiopia showed that 34.8% of the children had ac-
ceptable level of adherence when unannounced home
visit was made [30]. The wide difference here appears to
be driven by the nature of the visits (announced versus
unannounced or prior known visit). Possible explana-
tions for a low adherence in our study might be: (a) by
interviewing participants at home, we might have cap-
tured children who were at risk of being “lost to follow-
up”; in clinic-based studies these children would not
have been included; (b) we used non-medical staff to
collect information which may have reduced social desir-
ability bias; (c) measuring adherence by pill count usu-
ally shows low adherence levels compared to other
methods such as self-report [31] and lastly (d) our study
participants had an average treatment duration of 3 years,
and as the qualitative part outline treatment fatigue was
present.
Patients not staying with biological parents were more
likely to have poor adherence. Other studies found that
children’s adherence is affected by their dependence on
caretakers and that if adult caregivers are unavailable,
the risk of missed doses increases [32,33]. The successful
treatment of a child requires the commitment and in-
volvement of a responsible caregiver yet qualitative find-
ings showed that most often both parents and children
are concerned with the stigma related to disclosure of
HIV status to other family members or caretakers, friends
and schools teachers thus restricting the child’s options
for seeking support [10]. According to our participants,
the care given to HIV infected children by biological par-
ents was not the same as that given by non-parental care-
takers. This may be partly because some non-parental
caretakers were unaware of the child’s HIV status. In other
studies, disclosure was related to improved adherence to
ART medications and influenced children’s participation
in healthcare decision-making [34-37]. Health illiteracy
might be another issue surrounding poor adherence levels.
Compared to adults, children have lower levels of health
literacy and thus, following health care providers’directives
on maintaining adherence might not be easy for them
[32]. In times when children focus too much on playing
with friends, they tend to forget taking the drugs and
the situation worsens if their caretakers are not present.
Children who live with HIV-positive parents have the po-
tential additional benefit of the parental experience in liv-
ing with HIV and taking ART. However, we did not have
information on the HIV status of parents or caretakers.
Children with non-parental caretakers were older
(median age 11.4 versus 8.3 years) suggesting that some
adherence problems might be partially attributed to
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investigated further.
Secondary school aged children who had only primary
education or were still in primary school were more
likely to be non-adherent, although the association was
not significant. This may be partly explained by the fact
that 50% of these children were living with non-parental
caretakers, thus were at risk of less support to maintain
adequate adherence levels. The study’s qualitative part
provides another explanation for these findings. The
morning dose was challenging for children attending
school as they often have to leave for school early in the
morning before breakfast is ready. Competing demand
between taking the morning ART dose and rushing to
school make them vulnerable to skip their medications.
A study on how food insecurity impacts on non-
adherence to ART found that side effects were exacer-
bated when taking ART in the absence of food [38].
However, our study’s participants reside in a location
where food supply is quite stable and food shortage was
not reported as a barrier for optimal adherence in the
qualitative component. It was rather the school environ-
ment where HIV patients experienced mocking and seg-
regation which made it hard for them to take their ART
while at school and led to missing the morning dose. In
some settings HIV positive children attending school
were given names by their colleagues so as to victimize
them. In Namibia for instance, it was found that deroga-
tory terms have been used to discriminate HIV students
[39]. This impacts adherence levels as low social support
[40] and stigma has been identified in previous studies
to affect access to health care, social interaction and
medication adherence [41].
The association between adherence and SES, although
not significant, is in an unexpected direction; patients
coming from affluent families are at higher risk of poor
adherence. The effect of SES on adherence among HIV
infected patients is considered a controversial issue
[42-44]. Suggested pathways in which socioeconomic
status might be associated with adherence include edu-
cation's effect on shaping a financially stable future, and
on acquiring health literacy and knowledge to use health
resources, while income plays a big part in obtaining
better housing conditions, recreational facilities and bet-
ter health care [45]. However, a systematic review of the
evidence regarding the association of SES with adher-
ence to treatment of patients with HIV/AIDS found no
conclusive support for existence of a clear association
between the two variables [46]. From the explanatory
qualitative study, barriers of optimal adherence were un-
favorable school environment, patients being unaware of
their own HIV status, children feeling too shy to go to
collect medication at the clinic, parents’ failure to
disclose the children’s HIV status to family members/caretakers and differential care from non-parental
caretakers.
Strengths and limitations of the study
Apart from the strengths aforementioned, using a mixed
methods design allowed explanation and in-depth un-
derstanding of the quantitative results. The patients were
set in programmatic conditions i.e. not in a clinical trial
cohort with intensive support. The study covered a wide
time window, thus increasing generalizability and redu-
cing potential seasonality bias.
In addition to limitations of the methods used for
measuring adherence, selection bias may have resulted
from the rather high non-response rate of 25%. However
non-response analysis showed that variables under study
were not associated with non-response. In addition, we
performed sensitivity analysis (data not shown) for pre-
dictor variables with missing information and the results
were not considerably affected except WHO staging.
However WHO staging was taken from the clinic data-
base (and not the home visit) and was often missing due
to drug refill visits by someone other than the patient. In
some studies, pill count has been found to predict re-
sponse to ART [47], particularly when conducted with
no prior notification. However, in other studies, it has
been shown to be liable to pill dumping [48], fabrication,
and manipulation. Grouping a cohort of 2–19 year olds
together might have disguised specific adherence chal-
lenges for younger children (palatability, caregiver avail-
ability), which are very different from the challenges for
teenagers.
Implications
The implications of poor adherence for these children
might be that they experience worse clinical outcomes.
If this situation extends beyond our immediate setting,
both the current and future treatment options are under
threat if appropriate actions are not put in to place to
address adherence issues in children and teenagers. A
systematic review showed that almost a quarter of pa-
tients fail second-line therapy within 12 months, mainly
because of poor adherence rather than drug resistance
[49]. As this age group (12 + yrs) is becoming sexually
active, the likelihood of transmission of HIV increases
when the drugs are not taken properly and the virus is
not suppressed [50]. New efforts have to be made and
fully implemented to boost adherence to ART in this
important population.
The following recommendations could help improve
adherence among children and teenagers in settings
similar to ours: Parents and/or caretakers should counsel
and guide children on taking drugs parallel with provid-
ing a supportive environment at home i.e. family sup-
porter to ensure that during the parent’s absent children
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create conducive environment at home for children
i.e. make sure that food is ready before the child take
his/her dose especially in the morning. Counsellors
should improve counselling techniques and focus more
on how to overcome challenges that make children not
take their drugs as required. Furthermore, children should
have age-specific counseling services at HIV clinics separ-
ate from adults. This can be done at the HIV clinic or at
home during home-based care (HBC) visit. Assigned care-
takers (parents or non-parents) should disclose their
children’s HIV and ART status to household members
who will be able to provide support to children when par-
ents are absent. Health promotion messages should be tai-
lored to specific groups such as teachers, fellow students
as well as general community members to reduce their
stigmatizing behavior towards HIV positive children. Ad-
vocacy for the formulation of peer support groups in the
community and in schools should be encouraged to take a
lead in advocating for love, care and support for HIV in-
fected children.
Conclusion
In conclusion, evidence from this study suggests that,
children not living with both parents, are more likely to
have worse adherence to ART, in part due to an inad-
equate support environment in school and within the
nuclear or extended family.
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